"Oct. 17, 2012 -- A drug used to treat psoriasis may provide a much-needed option for people with bad cases of Crohn's disease.
In the new study, some people with moderate to severe Crohn's given Stelara (ustekinumab) began to see imp"...
Severe wheezing, 90 minutes after a second dose of sacrosidase, necessitated admission into the ICU for a 4-year old boy. The wheezing was probably caused by sacrosidase. He had asthma and was being treated with steroids. A skin test for sacrosidase was positive. Other serious events have not been linked to Sucraid® (sacrosidase oral solution) .
Care should be taken to administer initial doses of Sucraid® (sacrosidase oral solution) near (within a few minutes' travel) a facility where acute hypersensitivity reactions can be adequately treated. Alternatively, the patient may be tested for hypersensitivity to Sucraid® (sacrosidase oral solution) through skin abrasion testing. Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy. Skin testing as a rechallenge has been used to verify hypersensitivity in one asthmatic child who displayed wheezing after oral sacrosidase.
Although Sucraid® (sacrosidase oral solution) provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase. Therefore, restricting starch in the diet may still be necessary to reduce symptoms as much as possible. The need for dietary starch restriction for patients using Sucraid® (sacrosidase oral solution) should be evaluated in each patient. It may sometimes be clinically inappropriate, difficult or inconvenient to perform a small bowel biopsy or breath hydrogen test to make a definitive diagnosis of CSID. If the diagnosis is in doubt, it may be warranted to conduct a short therapeutic trial (e.g. one week) with Sucraid® (sacrosidase oral solution) to assess response in a patient suspected of sucrase deficiency.
The effects of SUCRAID (sacrosidase oral solution) have not been evaluated in patients with secondary (acquired) disaccharidase deficiencies.
Use in Diabetics
The use of Sucraid® (sacrosidase oral solution) will enable the products of sucrose hydrolysis- glucose and fructose to be absorbed. This fact must be carefully considered in planning the diet of diabetic CSID patients using Sucraid® (sacrosidase oral solution) .
The definitive test for diagnosis of CSID is the measurement of intestinal disaccharidases following small bowel biopsy. Other tests used alone may be inaccurate: for example, the breath hydrogen test (high incidence of false-negatives) or oral sucrose tolerance test (high incidence of false positives). Differential urinary disaccharide testing has been reported to show good agreement with small intestinal biopsy for diagnosis of CSID.
Carcinogenesis, Mutagenesis, Impirment Of Fertility
Long-term studies in animals with SUCRAID (sacrosidase oral solution) have not been performed to evaluate the carcinogenic potential. Studies to evaluate the effect of Sucraid® (sacrosidase oral solution) on fertility or its mutogenic potential have not been performed.
Teratogenic effects. Pregnancy Category C. Animal reproduction studies have not been conducted with Sucraid® (sacrosidase oral solution) . Sucraid® (sacrosidase oral solution) is not expected to cause fetal harm when administered to a pregnant woman or to affect reproductive capacity. Sucraid® (sacrosidase oral solution) should be given to a pregnant woman only if clearly needed.
The Sucraid® (sacrosidase oral solution) enzyme is broken down in the stomach and intestines and the component amino acids and peptides are then absorbed as nutrients.
Sucraid® (sacrosidase oral solution) has been used in patients as young as 5 months of age. Evidence in one controlled trial in primarily pediatric patients shows that Sucraid® (sacrosidase oral solution) is safe and effective for the treatment of the genetically acquired sucrase deficiency, which is part of CSID.
Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Sucraid Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.